Citius stock: A never-ending crash?

Citius stock is in deep crisis. With a loss of over 30 percent in just ten days and clear sell signals, the biotech stock is fighting for every cent.

Tectonic price fluctuations

On Friday, the stock fluctuated between $1.22 and $1.37 – a range that underscores its extreme volatility. The modest gain of 0.81 percent the previous day doesn't disguise the fact that the price swung by a whopping 7.69 percent in a single day. But what is really driving this rollercoaster ride?

Advertisement

If the extreme volatility of small caps is too risky for you, a free special report with five top stocks for 2025 reveals which pharmaceutical companies impress with strong pipelines. Request your 5 Top Stocks 2025 report now.

Alarming volume development

The trading volume of just 520,473 shares is significantly below the average of 838,322. Even more concerning: the volume plummeted by 188,000 shares on the last trading day. Are investors simply lacking faith in a trend reversal?

• Price drop: 31.32% in 10 days
• Trading volume: 38% below average
• Resistance zones: $1.40-$1.41

Technical analysis speaks a clear language: Both short-term and long-term moving averages are sending sell signals. A breakout above the $1.41 mark currently seems a long way off.

Advertisement

Should investors sell immediately? Or is it still worth investing in Citius ?

LYMPHIR™: Last Hope?

In the fourth quarter of 2025, Citius plans to launch LYMPHIR™ in the US market for the treatment of cutaneous T-cell lymphomas. Commercial production is underway, and packaging and distribution are organized. But can a single product stop the decline?

With a market capitalization of just $21 million, analyst targets seem almost surreal: The average price target of $53 stands in stark contrast to the current reality. The range between $6 and $100 reflects the extreme uncertainty – five analysts are currently only recommending a hold.

The biotech stock has experienced everything in the last 52 weeks: from $0.65 to $12.84. The question is: Will it now head back towards its lows?

Advertisement

Citius stock: Buy or sell?! New Citius analysis from November 9th provides the answer:

The latest Citius figures speak volumes: Citius shareholders urgently need to take action. Is it worth buying in, or should you sell? Our free analysis from November 9th will tell you what to do now.

Citius: Buy or sell? Read more here...